Ovarian cancer surgery in Maryland: Volume-based access to care

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 353-360

  Bristow, Robert E ^a   Zahurak, Mariana L ^b   Del Carmen, Marcela G ^a   Gordon, Toby A ^a   Fox, Harold E ^a   Trimble, Edward L ^a   Montz, F J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Access to care; Ovarian cancer; Surgery

Indexed keywords

ADULT; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH CARE; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURGEON; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYSTERECTOMY; LOGISTIC MODELS; MARYLAND; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE;

EID: 1942508957     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.02.010     Document Type: Article

References (51)

1. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics 2002. CA Cancer J. Clin. 52:2002;23-47.
2. NIH Consensus Development Panel on Ovarian Cancer Ovarian cancer screening, treatment, and follow-up. JAMA. 273:1995;491-497.
3. Hoskins W., Rice L., Rubin S. Ovarian cancer surgical practice guidelines. Oncology. 11:1997;896-904.
4. Carney M.E., Lancaster J.M., Ford C., Tsodikov A., Wiggins C.L. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol. Oncol. 84:2002;36-42.
5. Olaitan A., Weeks J., Mocroft A., Smith J., Howe K., Murdoch J. The surgical management of women with ovarian cancer in the south west of England. Br. J. Cancer. 85:2001;1824-1830.
6. Gershenson D.M. Why American women are not receiving state-of-the-art gynecologic cancer care. Cancer J. 7:2001;450-457.
7. Hillner B.E., Smith T.J., Desch C.E. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J. Clin. Oncol. 18:2000;2327-2340.
8. Cox D.R. The analysis of binary data. 1970;Methuen, London.
9. SAS Institute Inc. SAS user's guide: statistics. Fifth version edition:1985;SAS Institute Inc. Cary (NC).
10. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol. Oncol. 47:1992;203-209.
11. Junor E.J., Hole D.J., Gillis C.R. Management of ovarian cancer: referral to a multidisciplinary team matters. Br. J. Cancer. 70:1994;363-370.
12. Kehoe S., Powell J., Wilson S., Woodman C. The influence of the operating surgeon's specialization on patient survival in ovarian cancer. Br. J. Cancer. 70:1994;1014-1017.
13. Woodman C., Baghdady A., Collins S., Clyma J.A. What changes in the organization of cancer services will improve the outcome for women with ovarian cancer? Br. J. Obstet. Gynaecol. 104:1997;135-139.
14. Junor E.J., Hole D.J., McNulty L., Mason M., Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br. J. Obstet. Gynaecol. 106:1999;1130-1136.
15. McGowan L. Patterns of care in carcinoma of the ovary. Cancer. 71:1993;628-633.
16. Nguyen H.N., Averette H.E., Hoskins W., Penalver M., Sevin B.U., Steren A. National survey of ovarian carcinoma Part V. The impact of physician specialty on patients' survival. Cancer. 72:1993;3663-3670.
17. Puls L.E., Carrasco R., Morrow M.S., Blackhurst D. Stage I ovarian carcinoma: specialty-related differences in survival and management. South Med. J. 90:1997;1097-1100.
18. Grossi M., Quinn M.A., Thursfield V.J., Francis P.A., Rome R.M., Planner R.S.et al. Ovarian cancer: patterns of care in Victoria during 1993-1995. Med. J. Aust. 177:2002;11-16.
19. Mayer A.R., Chambers S.K., Graves E., Holm C., Tseng P.C., Nelson B.E.et al. Ovarian cancer staging: does it require a gynecologic oncologist? Gynecol. Oncol. 47:1992;223-227.
20. Voest E.E., van Houwelingen J.C., Neijt J.P. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur. J. Cancer Clin. Oncol. 25:1989;711-720.
21. Allen D.G., Heintz A.P.M., Touw F.W.M.M. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur. J. Gynaecol. Oncol. 16:1995;349-355.
22. Ben-David Y., Rosen B., Franssen E., Einarson T., Szyfer I. Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol. Oncol. 59:1995;93-101.
23. Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D.et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol. Oncol. 82:2001;532-537.
24. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20:2002;1248-1259.
25. Unzelman R.F. Advanced epithelial ovarian carcinoma: long-term survival experience at the community hospital. Am. J. Obstet. Gynecol. 166:1992;1663-1672.
26. Bertelson K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol. Oncol. 38:1990;203-209.
27. Del Campo J.M., Felip E., Rubio D., Vidal R., Bermejo B., Colomer R.et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol. Oncol. 53:1994;27-32.
28. Makar A.P., Baekelandt M., Tropé C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 56:1995;175-180.
29. Sengupta P.S., Jayson G.C., Slade R.J., Eardley A., Radford J.A. An audit of primary surgical treatment for women with ovarian cancer referred to a cancer center. Br. J. Cancer. 80:1999;444-447.
30. Piver M.S., Lele S.B., Marchetti D.L., Baker T.R., Tsukada Y., Emrich L.J. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J. Clin. Oncol. 6:1988;983-989.
31. Heintz A.P.M., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., Lagasse L.D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 67:1986;783-788.
32. Baker T.R., Piver M.S., Hempling R.E. Long term survival by cytoreductive surgery to less than 1cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma. Cancer. 74:1994;656-663.
33. Guidozzi F., Ball J.H.S. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol. Oncol. 53:1994;326-330.
34. van Dam P.A., Tjalma W., Weyler J., van Oosterom A.T., Buytaert P. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am. J. Obstet. Gynecol. 174:1996;943-950.
35. Michel G., De Iaco P., Castaigne D., el-Hassan M.J., Lobreglio R., Lhomme C.et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur. J. Gynaecol. Oncol. 18:1997;9-15.
36. Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69:1998;103-108.
37. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., Elashoff R.M. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet. Gynecol. 61:1983;413-420.
38. Piver M.S., Baker T. The potential for optimal (≤ 2cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol. Oncol. 24:1986;1-8.
39. Averette H.E., Hoskins W., Nguyen H.N., Boike G., Flessa H.C., Chmiel J.S.et al. National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons. Cancer. 71:1993;1629-1638.
40. Gordon T.A., Bowman H.M., Tielsch J.M., Bass E.B., Burleyson G.P., Cameron J.L. Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann. Surg. 228:1998;71-78.
41. Harmon J.W., Tang D.G., Gordon T.A., Bowman H.M., Choti M.A., Kaufman H.S.et al. Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Ann. Surg. 230:1999;404-413.
42. Gordon T.A., Bowman H.M., Bass E.B., Lillemoe K.D., Yeo C.J., Heitmiller R.F.et al. Complex gastrointestinal surgery: impact of provider experience on clinical and economic outcomes. J. Am. Coll. Surg. 189:1999;46-56.
43. Schrag D., Cramer L.D., Bach P.B., Cohen A.M., Warren J.L., Begg C.B. Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA. 284:2000;3028-3035.
44. Birkmeyer J.D., Finlayson S.R.G., Tosteson A.N.A., Sharp S.M., Warshaw A.L., Fisher E.S. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 125:1999;250-256.
45. Begg C.B., Cramer L.D., Hoskins W.J., Brennan M.F. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 280:1998;1747-1751.
46. Jolly K., Parry J., Rouse A., Stevens A. Volumes of cancer surgery for breast, colorectal and ovarian cancer 1992-97: is there evidence of increasing sub-specialization by surgeons? Br. J. Cancer. 84:2001;1308-1313.
47. Muntz H.G. "Curbside" consultations in gynecologic oncology: a closer look at a common practice. Gynecol. Oncol. 74:1999;456-459.
48. Mandelblatt J.S., Yabroff K.R., Kerner J.F. Equitable access to cancer services. A review of barriers to quality care. Cancer. 86:1999;2378-2390.
49. Munoz K.A., Harlan L.C., Trimble E.L. Patterns of care for women with ovarian cancer in the United States. J. Clin. Oncol. 15:1997;3408-3415.
50. Préfontaine M., Gruslin A. Referral patterns for suspected ovarian cancer: a survey of practicing gynecologists. Int. J. Gynaecol. Cancer. 5:1995;381-385.
51. Fitch M.I., Gray R.E., Covens A., Thomas G., Franssen E., DePetrillo D.et al. Gynecologists' perspectives regarding ovarian cancer. Cancer Prev. Control. 3:1999;68-76.